94 related articles for article (PubMed ID: 12713834)
21. Characterization and cellular distribution of the osteoclast ruffled membrane vacuolar H+-ATPase B-subunit using isoform-specific antibodies.
Mattsson JP; Skyman C; Palokangas H; Väänänen KH; Keeling DJ
J Bone Miner Res; 1997 May; 12(5):753-60. PubMed ID: 9144341
[TBL] [Abstract][Full Text] [Related]
22. Synthesis of photoactivatable acyclic analogues of the lobatamides.
Shen R; Inoue T; Forgac M; Porco JA
J Org Chem; 2005 Apr; 70(9):3686-92. PubMed ID: 15845008
[TBL] [Abstract][Full Text] [Related]
23. Interaction of inhibitors of the vacuolar H(+)-ATPase with the transmembrane Vo-sector.
Páli T; Whyteside G; Dixon N; Kee TP; Ball S; Harrison MA; Findlay JB; Finbow ME; Marsh D
Biochemistry; 2004 Sep; 43(38):12297-305. PubMed ID: 15379568
[TBL] [Abstract][Full Text] [Related]
24. [V-ATPase inhibitor baflomycine A1 inhibits bone resorption by osteoclast-like cells].
Zhao N; Yu S
Zhonghua Bing Li Xue Za Zhi; 1999 Dec; 28(6):436-9. PubMed ID: 11869558
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and V-ATPase inhibition of simplified lobatamide analogues.
Shen R; Lin CT; Bowman EJ; Bowman BJ; Porco JA
Org Lett; 2002 Sep; 4(18):3103-6. PubMed ID: 12201727
[TBL] [Abstract][Full Text] [Related]
26. Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins.
Petrangolini G; Supino R; Pratesi G; Dal Bo L; Tortoreto M; Croce AC; Misiano P; Belfiore P; Farina C; Zunino F
J Pharmacol Exp Ther; 2006 Sep; 318(3):939-46. PubMed ID: 16714402
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and structure-activity relationships of bafilomycin A1 derivatives as inhibitors of vacuolar H+-ATPase.
Gagliardi S; Gatti PA; Belfiore P; Zocchetti A; Clarke GD; Farina C
J Med Chem; 1998 May; 41(11):1883-93. PubMed ID: 9599238
[TBL] [Abstract][Full Text] [Related]
28. Specific inhibitors of vacuolar H(+)-ATPase trigger apoptotic cell death of osteoclasts.
Okahashi N; Nakamura I; Jimi E; Koide M; Suda T; Nishihara T
J Bone Miner Res; 1997 Jul; 12(7):1116-23. PubMed ID: 9200012
[TBL] [Abstract][Full Text] [Related]
29. Luteolin inhibition of V-ATPase a3-d2 interaction decreases osteoclast resorptive activity.
Crasto GJ; Kartner N; Yao Y; Li K; Bullock L; Datti A; Manolson MF
J Cell Biochem; 2013 Apr; 114(4):929-41. PubMed ID: 23129004
[TBL] [Abstract][Full Text] [Related]
30. Specific biological functions of vacuolar-type H(+)-ATPase and lysosomal cysteine proteinase, cathepsin K, in osteoclasts.
Sahara T; Itoh K; Debari K; Sasaki T
Anat Rec A Discov Mol Cell Evol Biol; 2003 Feb; 270(2):152-61. PubMed ID: 12524690
[TBL] [Abstract][Full Text] [Related]
31. Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases.
Mattsson JP; Väänänen K; Wallmark B; Lorentzon P
Biochim Biophys Acta; 1991 Jun; 1065(2):261-8. PubMed ID: 1647821
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis, and biological evaluation of novel analogues of archazolid: a highly potent simplified V-ATPase inhibitor.
Menche D; Hassfeld J; Sasse F; Huss M; Wieczorek H
Bioorg Med Chem Lett; 2007 Mar; 17(6):1732-5. PubMed ID: 17239591
[TBL] [Abstract][Full Text] [Related]
33. Vacuolar ATPase as a drug discovery target.
Niikura K
Drug News Perspect; 2006 Apr; 19(3):139-44. PubMed ID: 16804565
[TBL] [Abstract][Full Text] [Related]
34. Effects of Bafilomycin A1: an inhibitor of vacuolar H (+)-ATPases on endocytosis and apoptosis in RAW cells and RAW cell-derived osteoclasts.
Xu J; Feng HT; Wang C; Yip KH; Pavlos N; Papadimitriou JM; Wood D; Zheng MH
J Cell Biochem; 2003 Apr; 88(6):1256-64. PubMed ID: 12647307
[TBL] [Abstract][Full Text] [Related]
35. Concanamycin and indolyl pentadieneamide inhibitors of the vacuolar H+-ATPase bind with high affinity to the purified proteolipid subunit of the membrane domain.
Whyteside G; Meek PJ; Ball SK; Dixon N; Finbow ME; Kee TP; Findlay JB; Harrison MA
Biochemistry; 2005 Nov; 44(45):15024-31. PubMed ID: 16274249
[TBL] [Abstract][Full Text] [Related]
36. Binding assays of inhibitors towards selected V-ATPase domains.
Fernandes F; Loura LM; Fedorov A; Dixon N; Kee TP; Prieto M; Hemminga MA
Biochim Biophys Acta; 2006 Nov; 1758(11):1777-86. PubMed ID: 16996024
[TBL] [Abstract][Full Text] [Related]
37. Vacuolar H(+)-ATPases. Targets for drug discovery?
Keeling DJ; Herslöf M; Ryberg B; Sjögren S; Sölvell L
Ann N Y Acad Sci; 1997 Nov; 834():600-8. PubMed ID: 9405871
[No Abstract] [Full Text] [Related]
38. Synthesis and Evaluation of Cleistanthin A Derivatives as Potent Vacuolar H(+) -ATPase Inhibitors.
Zhao Y; Lu Y; Ma J; Zhu L
Chem Biol Drug Des; 2015 Oct; 86(4):691-6. PubMed ID: 25677205
[TBL] [Abstract][Full Text] [Related]
39. Incorporation of the V-ATPase inhibitors concanamycin and indole pentadiene in lipid membranes. Spin-label EPR studies.
Páli T; Dixon N; Kee TP; Marsh D
Biochim Biophys Acta; 2004 May; 1663(1-2):14-8. PubMed ID: 15157605
[TBL] [Abstract][Full Text] [Related]
40. Chemistry and structure activity relationships of bafilomycin A1, a potent and selective inhibitor of the vacuolar H+-ATPase.
Gagliardi S; Rees M; Farina C
Curr Med Chem; 1999 Dec; 6(12):1197-212. PubMed ID: 10519916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
